강직성 척추염 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 지역별

Ankylosing Spondylitis Market is estimated to be valued at USD 7.28 Bn in 2026 and is expected to reach USD 11.40 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.51% from 2026 to 2033.

The market is projected to witness steady growth owing to the rising prevalence of ankylosing spondylitis, increasing adoption of biologic therapies, expanding availability of biosimilars, and growing awareness regarding early diagnosis and disease management.

Ankylosing spondylitis (AS) is a chronic inflammatory autoimmune disorder that primarily affects the spine and sacroiliac joints, leading to pain, stiffness, and progressive loss of mobility. The disease can also affect peripheral joints and extra-articular organs, thereby significantly impacting quality of life. Growing awareness among healthcare professionals and patients, coupled with advancements in imaging technologies and biomarker-based diagnostics, is contributing to earlier diagnosis and improved treatment outcomes.

The market growth is further supported by increasing use of targeted biologic therapies, including tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) inhibitors, which have transformed the treatment landscape. Regulatory approvals of biosimilars and ongoing research in precision medicine are improving treatment accessibility and expanding therapeutic options. Organizations such as the Assessment of SpondyloArthritis International Society (ASAS), the American College of Rheumatology (ACR), and the European League Against Rheumatism (EULAR) continue to strengthen disease management guidelines, supporting wider adoption of advanced therapies.

Market Dynamics

The Ankylosing Spondylitis Market is driven by a combination of epidemiological, technological, and therapeutic factors.

One of the primary growth drivers is the increasing prevalence of ankylosing spondylitis and axial spondyloarthritis worldwide. Growing disease awareness and the availability of MRI-based diagnostic tools and HLA-B27 genetic testing are improving diagnosis rates and enabling early treatment intervention. Early diagnosis helps prevent structural damage and enhances long-term clinical outcomes, thereby driving demand for effective therapies.

Another major growth factor is the expanding use of biologics and targeted therapies. TNF inhibitors have become the standard treatment for moderate-to-severe disease, while IL-17 inhibitors have emerged as next-generation biologics offering therapeutic benefits for patients who do not adequately respond to anti-TNF agents. The rapid penetration of biosimilars across developed and emerging markets is lowering treatment costs and improving patient accessibility.

Technological innovations such as AI-assisted imaging analysis, digital biomarkers, electronic health records, wearable monitoring devices, and patient-reported outcome platforms are further enhancing disease monitoring and personalized care. These advancements are supporting better disease management and improving patient adherence to treatment.

However, the market faces challenges including high costs associated with biologic therapies, delayed diagnosis due to symptom overlap with other musculoskeletal disorders, and limited access to advanced treatments in low- and middle-income countries. Despite these restraints, ongoing investments in precision medicine, biomarker research, and next-generation targeted therapies are expected to create significant growth opportunities throughout the forecast period.

Key Features of the Study

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Ankylosing Spondylitis Market based on the following parameters - company highlights, service portfolio, key developments, financial performance, and strategies
• Key companies covered as a part of this study include Amgen Inc., AbbVie Inc., Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Emcure Pharmaceuticals, Torrent Pharmaceuticals Ltd., UCB S.A., Suzhou Zelgen Biopharmaceuticals Co., Ltd., HENGRUI USA, and Johnson & Johnson Services, Inc.
• Insights from this report would allow marketers and management authorities to make informed decisions regarding future service innovations, market expansion, and strategic partnerships
• The Ankylosing Spondylitis Market report caters to various stakeholders including investors, service providers, pharmaceutical companies, regulatory bodies, and financial analysts
• Stakeholders would benefit from structured analytical frameworks and strategy matrices used in evaluating the Ankylosing Spondylitis Market.

Market Segmentation

• By Drug Type (Revenue, USD Bn, 2021-2033)
• Nonsteroidal anti-inflammatory drugs (NSAIDs)
• Disease-modifying anti-rheumatic drugs (DMARDs)
• TNF Inhibitors
• Corticosteroids
• Others
• By Route of Administration (Revenue, USD Bn, 2021-2033)
• Oral
• Parenteral
• By Distribution Channel (Revenue, USD Bn, 2021-2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region (Revenue, USD Bn, 2021-2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • Central Africa
  • North Africa
• Key Players
• Amgen Inc.
• AbbVie Inc.
• Pfizer Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• CELGENE CORPORATION
• Eli Lilly and Company
• Cipla Inc.
• Emcure Pharmaceuticals
• Torrent Pharmaceuticals Ltd.
• UCB S.A.
• Suzhou Zelgen Biopharmaceuticals Co., Ltd.
• HENGRUI USA
• Johnson & Johnson Services, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Product Approval
• Collaboration/Merge/Acquisition
• Regulatory Landscape
• PEST Analysis
• Porter's Five Forces Analysis
• Epidemiology
• Robust Pipeline Analysis

4. Ankylosing Spondylitis Market, By Drug Type, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Disease-modifying Anti-rheumatic Drugs (DMARDs)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• TNF Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Corticosteroids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Ankylosing Spondylitis Market, By Route of Administration, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Ankylosing Spondylitis Market, By Distribution Channel, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Ankylosing Spondylitis Market, By Region, 2021 - 2033, (USD Billion)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2022-2033
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
    • North Africa
    • Central Africa
    • South Africa

8. Competitive Landscape

• Heat Map Analysis
• Market Share Analysis
• Company Profile
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • AbbVie Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Bristol-Myers Squibb Company
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • CELGENE CORPORATION
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Cipla Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Emcure Pharmaceuticals
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Torrent Pharmaceuticals Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • UCB S.A.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Suzhou Zelgen Biopharmaceuticals Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • HENGRUI USA
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
  • Johnson & Johnson Services, Inc.
    • Company Highlights
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Market Strategies
• Analyst Views

9. Section

• References
• Research Methodology
• About Us